文献速递眼底病与葡萄膜炎

玻璃体内注射ziv-aflibercept治疗视网膜疾病的长期安全性与疗效

Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
PubMed 文献 · Br J Ophthalmol · 2017-03-07

在三个中心连续观察65只眼接受6次及以上玻璃体内注射ziv-aflibercept(1.25 mg)的视网膜疾病患者,平均随访9.2个月。第6次注射后平均最佳矫正视力(BCVA)和中心黄斑厚度(CMT)均改善,随访9个月和1年时仍维持改善;未观察到眼压升高、晶状体混浊进展或眼内炎,仅1例出现一过性轻度虹膜炎。

要点

  • 65只眼平均接受8.4次注射,第6次注射后平均BCVA从0.98改善至0.57(p=0.001),CMT从432.7 μm降至274.8 μm(p=0.0001)。
  • 随访9个月时19只眼平均BCVA为0.62(p=0.0004),CMT为292.0 μm(p<0.01);1年时7只眼平均BCVA为0.73,CMT为311.6 μm。
  • 仅1例在第4次注射后出现一过性轻度虹膜炎,后续注射未再发生;未观察到眼压升高、晶状体混浊进展或眼内炎。

核心结论

  • 反复玻璃体内注射ziv-aflibercept在视网膜疾病治疗中似乎可耐受、安全且有效。

研究设计与样本

  • 连续纳入三个中心接受6次及以上玻璃体内注射0.05 mL ziv-aflibercept(1.25 mg)的视网膜疾病患者,每月随访。
  • 共65只眼(60例连续患者),平均接受8.4次(范围6-17次)注射,平均随访9.2个月(范围6-18个月)。
  • 采用Wilcoxon符号秩检验进行配对比较。

主要发现

  • 基线平均logMAR BCVA为0.98±0.56,CMT为432.7±163.0 μm。
  • 第6次注射后平均BCVA改善至0.57±0.36(p=0.001),CMT降至274.8±117.8 μm(p=0.0001)。
  • 9个月随访时19只眼平均BCVA改善至0.62±0.37(p=0.0004),平均CMT降至292.0±160.9 μm(p<0.01)。
  • 1年时7只眼平均BCVA为0.73±0.52,CMT为311.6±232.5 μm。
  • 注射后眼压未升高;1例在第4次注射后出现一过性轻度虹膜炎,后续注射未再发生;未观察到晶状体混浊进展或眼内炎;未记录到全身不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. METHODS: Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise. Paired comparison was done using Wilcoxon signed-rank test calculator. RESULTS: Sixty-five eyes of 60 consecutive patients received a mean of 8.4 (6-17) intravitreal injections with a baseline mean logMAR BCVA of 0.98±0.56 and CMT 432.7±163.0 μm and followed for a mean of 9.2 months (range 6-18 months). After the sixth injection, mean BCVA improved to 0.57±0.36 (p=0.001) and CMT decreased to 274.8±117.8 μm (p=0.0001). At the 9-month follow-up, mean BCVA improved to 0.62±0.37 (p=0.0004) and mean CMT decreased to 292.0±160.9 μm (p<0.01) in 19 eyes. At 1 year, mean BCVA was 0.73±0.52 and CMT 311.6±232.5 μm in seven eyes. Intraocular pressures did not increase after injections. One subject developed transient mild iritis at the fourth injection but not on subsequent injections. No lens opacity progression or endophthalmitis was noted. Systemic adverse effects were not registered. CONCLUSIONS: Repeated intravitreal injections of ziv-aflibercept appear tolerable, safe and efficacious in the therapy of retinal disease.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mansour AM, Ashraf M, Dedhia CJ, et al. Long-term safety and efficacy of ziv-aflibercept in retinal diseases. Br J Ophthalmol. 2017. PMID: 28270485. doi:10.1136/bjophthalmol-2016-309724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。